Robert H. Shoemaker

National Cancer Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

58h-index24.2kcitations340works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(34), Cancer Research and Treatments(27), Immunotherapy and Immune Responses(26), Computational Drug Discovery Methods(25), RNA Interference and Gene Delivery(23)

Publications339 total

The Establishment of Prostate-specific, SKP2 Humanized Mice by CRISPR Knock-in Method Reveals Neoplastic Initiation and Microenvironmental Reprogramming
2026Open Access
Yes, It Is Worth It: Consider Participant Experiences in the Design of Future Trials
Cancer Prevention Research·2026
High-grade serous ovarian cancer induced in different sites of origin in mice exemplifies diverse features of the human disease
iScience·2025Open Access
Editor’s Note: Werner Syndrome Helicase Has a Critical Role in DNA Damage Responses in the Absence of a Functional Fanconi Anemia Pathway
Cancer Research·2025Open Access
Development of a Stable Lyophilized Formulation of a Quadrivalent Frame-Shift Peptide Vaccine for Cancer Prevention in Lynch Syndrome
2025Open Access
Immunoprevention of non-viral cancers: challenges and strategies for early intervention
Cancer Cell International·2025Open Access
Abstract 6343: Frameshift neoantigen-based vaccine testing in an intra-cecal implantation mouse model of Lynch syndrome
Cancer Research·2025
Abstract 6337: A novel PMS2 mutant Lynch syndrome mouse model for cancer prevention studies
Cancer Research·2025
Abstract 3531: Development of a mRNA-LNP vaccine for Lynch syndrome
Cancer Research·2025
Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice
Vaccine·2024· 6 citedOpen Access
Frameshift mutation spectra overlap between constitutional mismatch repair deficiency tumors and Lynch syndrome tumors
Journal of Clinical Investigation·2024Open Access
316 (PB304): Targeting prostein (SLC45A3) and ERG for interception of prostate cancer using self-amplifying RNA vaccines
European Journal of Cancer·2024
Data from NCI Resources for Cancer Immunoprevention Research
2024Open Access
Supplementary Table S1 from NCI Resources for Cancer Immunoprevention Research
2024Open Access
Supplementary Table S1 from NCI Resources for Cancer Immunoprevention Research
2024Open Access
Data from NCI Resources for Cancer Immunoprevention Research
2024Open Access
Abstract 4778: Development of self-amplifying RNA vaccines targeting prostate tissue-restricted and tumor-associated antigens
Cancer Research·2024
Abstract 1445: Emergence of frameshift mutations during tumorigenesis in VCMsh2 mouse model of Lynch syndrome
Cancer Research·2024
Effect of nonsteroidal anti‐inflammatory drugs (aspirin and naproxen) on inflammation‐associated proteomic profiles in mouse plasma and prostate during <i>TMPRSS2‐ERG</i> (fusion)‐driven prostate carcinogenesis
Molecular Carcinogenesis·2024· 4 citedOpen Access
Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome
JNCI Journal of the National Cancer Institute·2024· 3 citedOpen Access
page 1 of 17Next →

Frequent Co-authors

Michael R. Boyd(13), Dominic A. Scudiero(12), Anne Monks(9), Giovanni Melillo(7), Shizuko Sei(6), Kenneth D. Paull(5), Annamaria Rapisarda(5), Badarch Uranchimeg(5), Wolfgang Walther(5), Ulrike Stein(5), Melinda G. Hollingshead(4), Aldo Andreani(4), Massimiliano Granaiola(4), Alessandra Locatelli(4), Rita Morigi(4), Mirella Rambaldi(4), Lucilla Varoli(4), David T. Vistica(3), Michael C. Alley(3), Donald L. Fine(3)